✓ Medically Reviewed Monograph

Ursodeoxycholic Acid

Also known as / Synonyms: Ursodiol, UDCA, Ursodeoxycholic Acid

Naturally occurring hydrophilic bile acid treating cholestatic liver disease and dissolving gallstones.

Medically reviewed by Dr. Lisa Matthews, PharmD BCPS · Clinical Pharmacist
Written by 4mg Clinical Pharmacology Team Last reviewed ✓ Clinically Verified
📋

Clinical Snapshot & Specifications

Generic Name: Ursodeoxycholic Acid
Active Ingredient: Ursodeoxycholic Acid
Dosage Form: Tablet
Available Strengths: 150 mg, 300 mg, 450 mg, 600 mg tablets
Prescription Status: Prescription only (Schedule H / verified)
Approved Routes:
Oral
Popular Verified Brands:
Udiliv Urso Ursocol Livostep Golbi (India)
Regulatory Standards: CDSCO approved; Schedule H prescription drug. First-line therapy for primary biliary cholangitis.
🎯

Approved Indications & Medical Uses

  • Treatment of primary biliary cholangitis (PBC) to delay disease progression.
  • Dissolution of radiolucent, non-calcified gallstones (< 20 mm) in patients with a functioning gallbladder.
  • Intrahepatic cholestasis of pregnancy (ICP) for relief of pruritus and transaminase normalization.
  • Nonalcoholic steatohepatitis (NASH) and cystic fibrosis-related hepatobiliary disease (adjunctive).
🚫

Contraindications (Do Not Use If…)

  • Calcified or radiopaque gallstones, pigment stones, or non-functioning gallbladder.
  • Acute cholecystitis, acute cholangitis, or complete biliary tract obstruction.
  • Severe hepatic failure or active peptic ulcer disease.
  • Known hypersensitivity to ursodeoxycholic acid or bile acids.
🛡️

Important Clinical Precautions & Warnings

  • Liver function monitoring: monitor AST, ALT, alkaline phosphatase, and bilirubin monthly for the first 3 months, then every 6 months.
  • Gallstone dissolution criteria: requires serial ultrasound monitoring every 6 months; therapy may take 6 to 24 months.
  • Strict compliance: gallstones may recur after cessation of therapy.
  • Take with meals or milk to enhance intestinal emulsification and absorption.

Special Populations (Paediatric & Geriatric Care)

Pediatric: Used in cystic fibrosis-related liver disease (ages >= 6 years); dosage 20 mg/kg/day. Elderly: No specific dosage restrictions; monitor liver biochemistry.

⚡

Side Effects & Adverse Reactions

ℹ️ Common Side Effects (Usually Mild)

Diarrhea or loose stools, nausea, abdominal discomfort, indigestion, rash, and transient hair thinning.

🚨 Serious Side Effects — Seek Urgent Medical Care

Biliary colic from mobilizing gallstones, severe hepatotoxicity, calcification of gallstones, and hypersensitivity reactions.

Action: Discontinue medication and seek immediate medical attention or call emergency services if any serious symptom occurs.

🔄

Drug, Food & Substance Interactions

  • Bile acid sequestrants (cholestyramine, colestipol): bind UDCA in the gut and eliminate its efficacy; space by >= 4 hours.
  • Aluminum hydroxide antacids: decrease UDCA absorption.
  • Estrogens and oral contraceptives: increase biliary cholesterol secretion, countering gallstone dissolution.
  • Ciprofloxacin and dapsone: potential altered bioavailability.
🤰

Pregnancy & Lactation Clinical Safety

Pregnancy Safety:

Use with caution — see notes

Widely utilized and guideline-endorsed in the 2nd and 3rd trimesters for intrahepatic cholestasis of pregnancy (ICP); consult obstetrician.

Lactation & Breastfeeding:

Use with caution — see notes

Excretion in human milk is negligible; no adverse events have been noted in nursing infants.

📦

Storage, Administration & Overdose Protocol

🌡️ Recommended Storage:

Store below 30°C in a dry place. Protect from heat and direct sunlight.

⏱️ Missed Dose Protocol:

Take in divided doses with food, or single dose at bedtime. If forgotten, take with the next meal. Do not take double tablets.

📚

Clinical Sources & Regulatory References

Statutory drug monograph citations and regulatory databases consulted for clinical synthesis.

Every clinical monograph on 4mg.in is continuously cross-referenced against official pharmacopoeias, national formulary compendia, and statutory regulatory filings to guarantee therapeutic precision:

🏛️ CDSCO (Govt. of India)

Central Drugs Standard Control Organisation, Ministry of Health and Family Welfare. Evaluated for approved indications, Schedule H/H1 status, and National List of Essential Medicines (NLEM).

CDSCO Official Portal →
🇺🇸 U.S. FDA / DailyMed

U.S. Food and Drug Administration Approved Prescribing Information, Package Inserts, and Pharmacovigilance Black Box Warnings repository via NLM DailyMed.

Search FDA Labels on DailyMed →
🌐 World Health Organization

WHO Model List of Essential Medicines (23rd List) and WHO Collaborating Centre for Drug Statistics Methodology (Anatomical Therapeutic Chemical - ATC / DDD Index).

WHO Essential Medicines Registry →
🔬 PubMed / NLM

National Center for Biotechnology Information (NCBI). Peer-reviewed clinical trials, bioavailability investigations, and Cochrane systematic reviews.

Query PubMed Studies for Ursodeoxycholic Acid →
Suggested Monograph Citation:

4mg Clinical Pharmacology Team. Ursodeoxycholic Acid Monograph: Uses, Dosage, Contraindications & Interactions. Medically reviewed by licensed clinical editors. 4mg.in, 2026. Available at: https://4mg.in/medicines/ursodeoxycholic-acid/

🛡️
Clinical & Legal Disclaimer: The clinical monographs and drug information published on 4mg.in are strictly intended for educational, clinical reference, and informational utility. They do not constitute personalized medical advice, diagnosis, or treatment regimens. Always seek the advice of a registered physician or licensed pharmacist regarding specific clinical conditions, prescription dosages, and potential contraindications. Review our comprehensive Editorial & Clinical Fact-Checking Policy.